Sign up to save your podcasts
Or
Share FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo
Welcome to the Oncology Brothers Podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Saby George from Roswell Park Comprehensive Cancer Center to discuss the recent approval of subcutaneous nivolumab based on the CheckMate-67T study.
Join us as we delve into:
• The study design and findings of CheckMate-67T
• The implications of subcutaneous nivolumab for patients and healthcare providers
• Safety signals and side effects associated with the new formulation
• The significant time savings for patients receiving treatment
• Real-world experiences from patients involved in the trial
This episode highlights how the subcutaneous formulation of nivolumab can enhance patient care by reducing time spent in infusion centers while maintaining efficacy and safety.
Tune in to learn more about this exciting advancement in cancer treatment and its potential impact on patient quality of life! Don't forget to like, subscribe, and check out our other episodes for more insights on FDA drug approvals, conference highlights, and treatment algorithms. We are the Oncology Brothers!
YouTube: https://youtu.be/4blP8jqizUQ
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Subscribe to our channel for more insights on oncology treatments and patient care!
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome to the Oncology Brothers Podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Saby George from Roswell Park Comprehensive Cancer Center to discuss the recent approval of subcutaneous nivolumab based on the CheckMate-67T study.
Join us as we delve into:
• The study design and findings of CheckMate-67T
• The implications of subcutaneous nivolumab for patients and healthcare providers
• Safety signals and side effects associated with the new formulation
• The significant time savings for patients receiving treatment
• Real-world experiences from patients involved in the trial
This episode highlights how the subcutaneous formulation of nivolumab can enhance patient care by reducing time spent in infusion centers while maintaining efficacy and safety.
Tune in to learn more about this exciting advancement in cancer treatment and its potential impact on patient quality of life! Don't forget to like, subscribe, and check out our other episodes for more insights on FDA drug approvals, conference highlights, and treatment algorithms. We are the Oncology Brothers!
YouTube: https://youtu.be/4blP8jqizUQ
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Subscribe to our channel for more insights on oncology treatments and patient care!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
322 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
288 Listeners
White Coat Investor Podcast
2,435 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
The ONS Podcast
199 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Two Onc Docs
185 Listeners